Glucocorticoid resistance in T-lineage acute lymphoblastic leukaemia is associated with a proliferative metabolism

Beesley, A. H.; Firth, M. J.; Ford, J.; Weller, R. E.; Freitas, J. R.; Perera, K. U.; Kees, U. R.
June 2009
British Journal of Cancer;6/16/2009, Vol. 100 Issue 12, p1926
Academic Journal
Glucocorticoids (GCs) are among the most important drugs for acute lymphoblastic leukaemia (ALL), yet despite their clinical importance, the exact mechanisms involved in GC cytotoxicity and the development of resistance remain uncertain. We examined the baseline profile of a panel of T-ALL cell lines to determine factors that contribute to GC resistance without prior drug selection. Transcriptional profiling indicated GC resistance in T-ALL is associated with a proliferative phenotype involving upregulation of glycolysis, oxidative phosphorylation, cholesterol biosynthesis and glutamate metabolism, increased growth rates and activation of PI3K/AKT/mTOR and MYC signalling pathways. Importantly, the presence of these transcriptional signatures in primary ALL specimens significantly predicted patient outcome. We conclude that in lymphocytes the activation of bioenergetic pathways required for proliferation may suppress the apoptotic potential and offset the metabolic crisis initiated by GC signalling. It is likely that the link between GC resistance and proliferation in T-ALL has not been fully appreciated to date because such effects would be masked in the context of current multiagent therapies. The data also provide the first evidence that altered expression of wild-type MLL may contribute to GC-resistant phenotypes. Our findings warrant the continued development of selective metabolic inhibitors for the treatment of ALL.British Journal of Cancer (2009) 100, 1926–1936; doi:10.1038/sj.bjc.6605072; published online 12 May 2009; www.bjcancer.com


Related Articles

  • γ-secretase inhibitors reverse glucocorticoid resistance in T cell acute lymphoblastic leukemia. Real, Pedro J.; Tosello, Valeria; Palomero, Teresa; Castillo, Mireia; Hernando, Eva; de Stanchina, Elisa; Sulis, Maria Luisa; Barnes, Kelly; Sawai, Catherine; Homminga, Irene; Meijerink, Jules; Aifantis, Iannis; Basso, Giuseppe; Cordon-Cardo, Carlos; Ai, Walden; Ferrando, Adolfo // Nature Medicine;Jan2009, Vol. 15 Issue 1, p50 

    Gamma-secretase inhibitors (GSIs) block the activation of the oncogenic protein Notch homolog-1 (NOTCH1) in T cell acute lymphoblastic leukemia (T-ALL). However, limited antileukemic cytotoxicity and severe gastrointestinal toxicity have restricted the clinical application of these targeted...

  • Induction of autophagy-dependent necroptosis is required for childhood acute lymphoblastic leukemia cells to overcome glucocorticoid resistance. Bonapace, Laura; Bornhauser, Beat C.; Schmitz, Maike; Cario, Gunnar; Ziegler, Urs; Niggli, Felix K.; Schäfer, Beat W.; Schrappe, Martin; Stanulla, Martin; Bourquin, Jean-Pierre; Schäfer, Beat W // Journal of Clinical Investigation;Apr2010, Vol. 120 Issue 4, p1310 

    In vivo resistance to first-line chemotherapy, including to glucocorticoids, is a strong predictor of poor outcome in children with acute lymphoblastic leukemia (ALL). Modulation of cell death regulators represents an attractive strategy for subverting such drug resistance. Here we report...

  • MEK inhibitors potentiate dexamethasone lethality in acute lymphoblastic leukemia cells through the pro-apoptotic molecule BIM. Rambal, A. A.; Panaguiton, Z. L. G.; Kramer, L.; Grant, S.; Harada, H. // Leukemia (08876924);Oct2009, Vol. 23 Issue 10, p1744 

    Glucocorticoids (GCs) are common components of many chemotherapeutic regimens for lymphoid malignancies. GC-induced apoptosis involves an intrinsic mitochondria-dependent pathway. We and others have shown that BIM (BCL-2 interacting mediator of cell death), a BH3-only pro-apoptotic protein, is...

  • Effects of inhibitors of the chemokine receptor CXCR4 on acute lymphoblastic leukemia cells in vitro. Juarez, J; Bradstock, K F; Gottlieb, D J; Bendall, L J // Leukemia (08876924);Jul2003, Vol. 17 Issue 7, p1294 

    Stromal cell-derived factor-1 (SDF-1) is a key regulator of the behavior of normal and leukemic precursor-B (pre-B) cells. It is possible that inhibiting SDF-1-driven processes in pre-B acute lymphoblastic leukemia (ALL) may have therapeutic implications. In this study, we examined the ability...

  • Dose reduction of coadministered 6-mercaptopurine decreases myelotoxicity following high-dose methotrexate in childhood leukemia. Nygaard, U; Schmiegelow, K // Leukemia (08876924);Jul2003, Vol. 17 Issue 7, p1344 

    High-dose methotrexate (HDM) given concurrently with oral 6-mercaptopurine (6 MP) may be followed by myelotoxicity, which may necessitate treatment interruption and thus interfere with the efficacy of the treatment of childhood acute lymphoblastic leukemia (ALL). Through inhibition of purine de...

  • Beta-chemokines are released from HIV-1-specific cytolytic T-cell granules complexed to proteoglycans. Wagner, Ludwig; Yang, Otto O.; Garcia-Zepeda, Eduardo A.; Ge, Yimin; Kalams, Spyros A.; Walker, Bruce D.; Pasternack, Mark S.; Luster, Andrew D. // Nature;2/26/1998, Vol. 391 Issue 6670, p908 

    Presents research which showed that granzyme A and RANTES are both localized in the cytolytic granules of HIV-1-specific CD8+ cytotoxic T lymphocytes (CTL). Role of CD8+ lymphocytes in HIV-1; Comparison of cytolytic and noncytolytic pathways; Markers used; Mediators secreted together;...

  • Novel small molecule drugs inhibit tumor cell metabolism and show potent anti-tumorigenic potential. Trojel-Hansen, Christina; Erichsen, Kamille; Christensen, Mette; Jensen, Peter; Sehested, Maxwell; Nielsen, Søren // Cancer Chemotherapy & Pharmacology;Jul2011, Vol. 68 Issue 1, p127 

    Background: Rapidly dividing tumor cells have an increased demand for nutrients to support their characteristic unabated growth; this demand is met by an increased availability of nutrients such as amino acids through vasculogenesis and by the enhanced cellular entry of nutrients through the...

  • Rituximab mediates in vitro antileukemic activity in pediatric patients after allogeneic transplantation. Pfeiffer, M.; Stanojevic, S.; Feuchtinger, T.; Greil, J.; Handgretinger, R.; Barbin, K.; Jung, G.; Martin, D.; Niethammer, D.; Lang, P. // Bone Marrow Transplantation;Jul2005, Vol. 36 Issue 2, p91 

    Summary:Relapse is a major problem after allogeneic transplantation in children with acute B-lineage lymphoblastic leukemias (ALL) and lymphomas and additional therapeutic strategies are needed to increase graft versus leukemia effects without inducing graft versus host disease (GvHD). Several...

  • T cells stimulated by CD40L positive leukemic blasts-pulsed dendritic cells meet optimal functional requirements for adoptive T-cell therapy. D'Amico, G. D.; Bonamino, M.; Dander, E.; Marin, V.; Basso, G.; Balduzzi, A.; Biagi, E.; Biondi, A. // Leukemia (08876924);Nov2006, Vol. 20 Issue 11, p2015 

    Adoptive T-cell immunotherapy may provide complementary therapy for childhood B-cell precursor acute lymphoblastic leukemia (BCP-ALL). In this study, we have analyzed the functional characteristics of anti-BCP-ALL effector T cells generated by co-culturing T lymphocytes and dendritic cells (DC)...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics